AURA — Aura Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1501796 ·
Last close
$6.51
Market Cap
$674.60M
52W High
$9.53
52W Low
$4.73
ADV30
887,233
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -48,069,000 | -45,637,000 | 348,129,000 | 67,836,000 | 32,862,000 |
| Mar 2026 | 0 | — | -34,866,000 | -33,685,000 | 137,677,000 | 84,793,000 | 30,430,000 |
| Dec 2025 | 0 | — | -27,237,000 | -25,559,000 | 169,430,000 | 59,515,000 | 32,517,000 |
| Sep 2025 | 0 | — | -27,906,000 | -26,130,000 | 190,024,000 | 47,553,000 | 33,357,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,280,000
Investing CF
$60,680,000
Financing CF
$77,359,000
CapEx
$-362,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-514,103,000
Inventory
—
Receivables
—
ST Investments
$29,940,000
EBIT TTM
$-118,622,000
Pretax Income TTM
$-112,293,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -112,791,000 | -106,191,000 | 169,430,000 | 32,517,000 | 136,913,000 | -84,742,000 |
| Dec 2024 | 0 | -96,116,000 | -86,919,000 | 182,503,000 | 30,533,000 | 151,970,000 | -79,805,000 |
| Dec 2023 | 0 | -84,991,000 | -76,408,000 | 255,075,000 | 29,227,000 | 225,848,000 | -63,847,000 |
| Dec 2022 | 0 | -60,295,000 | -58,763,000 | 223,935,000 | 28,352,000 | 195,583,000 | -54,601,000 |
TTM Snapshot
Revenues TTM
$134,361,000
NetIncome TTM
$-112,393,000
OpCashFlow TTM
—
Assets (Latest)
$137,677,000
Forward EPS
$-2.03
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $6.54 · call volume: 13 · put volume: 0
Expected Move to 2027-01-15:
±$4.45
(68.04%) —
implied range
$2.09 –
$10.99
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRME | Prime Medicine, Inc. | $649.33M | $3.58 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $701.60M | $12.70 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $628.05M | $11.34 | — |
| SLDB | Solid Biosciences Inc. | $731.28M | $6.82 | — |
| CADL | Candel Therapeutics, Inc. | $739.17M | $9.66 | — |
News headlines (Yahoo Finance, 1h cache)
Aura Biosciences to Participate in Upcoming Investor Conference
2026-09-02 20:01 · Yahoo
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:28 · Yahoo
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-11 11:00 · Yahoo
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
2026-06-01 12:00 · Yahoo
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
2026-05-27 20:04 · Yahoo
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
2026-05-20 02:02 · Yahoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-11 20:01 · Yahoo
Aura Biosciences to Participate in Upcoming Investor Conferences
2026-05-12 20:01 · Yahoo
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-05-04 10:03 · Yahoo
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
2026-05-04 13:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.